Paroxysmal Nonepileptic Events in Children With Epilepsy and Cerebral Palsy

Monica S Cooper1,2,3, Michael C Fahey4, Charuta Dagia5

  • 1Department of Neurodevelopment & Disability, Royal Children's Hospital, Melbourne, Parkville, Victoria, Australia.

Insights

Paroxysmal nonepileptic events are common in children with cerebral palsy and epilepsy. Clearer counseling is needed to help parents distinguish these events from epileptic seizures, improving diagnosis and care.

Area of Science:

  • Neurology
  • Pediatrics
  • Epileptology

Background:

  • Cerebral palsy (CP) is a common neurodevelopmental disorder.
  • Epilepsy frequently co-occurs with CP, often stemming from brain injury.
  • Differentiating epileptic from nonepileptic events in this population is clinically challenging.

Purpose of the Study:

  • To ascertain the incidence of paroxysmal nonepileptic events (PNEs) in children with CP and epilepsy.
  • To identify factors associated with PNEs in this cohort.
  • To assess the accuracy of parental/carer event reporting.

Main Methods:

  • Retrospective, population-based cohort study utilizing the Victorian CP Register (birth years 1999-2006).
  • Analysis of neuroimaging, medical records, and electroencephalograms (EEGs) with video correlation.
  • Inclusion criteria: children with CP due to brain injury and diagnosed epilepsy.

Main Results:

  • Of 256 children with CP, 87 had epilepsy; 82 had analyzable EEGs.
  • Epileptic events were captured on EEG in 22% (18/82) of children.
  • Paroxysmal nonepileptic events were captured on EEG in 26% (21/82) of children.
  • 77% (13/18) of children with epileptic events also had PNEs.
  • Parental/carer reporting misattributed PNEs as epileptic in 10 cases.

Conclusions:

  • Approximately one-fourth of children with CP and epilepsy in this cohort exhibited PNEs on EEG.
  • A significant proportion of reported nonepileptic events were misclassified by caregivers.
  • Enhanced patient and caregiver education on seizure semiology is crucial for accurate diagnosis in children with CP and epilepsy.

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
453
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
230
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
223
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
437
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
702